Bleakley Financial Group LLC Sells 1,903 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bleakley Financial Group LLC lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 26.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,290 shares of the medical device company’s stock after selling 1,903 shares during the period. Bleakley Financial Group LLC’s holdings in DexCom were worth $355,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Waters Parkerson & CO. LLC increased its holdings in DexCom by 4.2% during the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after acquiring an additional 10,892 shares during the period. Legal & General Group Plc increased its holdings in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after acquiring an additional 49,076 shares during the period. Factory Mutual Insurance Co. increased its holdings in DexCom by 136.1% during the 3rd quarter. Factory Mutual Insurance Co. now owns 404,230 shares of the medical device company’s stock worth $27,100,000 after acquiring an additional 233,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of DexCom by 533.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock worth $4,140,000 after buying an additional 30,743 shares during the last quarter. Finally, Mattson Financial Services LLC bought a new position in shares of DexCom in the 2nd quarter worth $2,003,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock valued at $126,390 in the last quarter. Company insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.6 %

Shares of DXCM opened at $73.08 on Wednesday. The stock has a market capitalization of $29.06 billion, a P/E ratio of 47.15, a PEG ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The firm has a fifty day simple moving average of $70.03 and a two-hundred day simple moving average of $99.06. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.34 EPS. On average, research analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Wells Fargo & Company decreased their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, October 12th. Piper Sandler reissued an “overweight” rating and issued a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Finally, BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.73.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.